Relevium Technologies Inc.
Relevium Technologies Inc.
Your view on RLLVF
Overview
What the company does, where it operates, and who runs it.
About Relevium Technologies Inc.
- Industry
- Medical - Pharmaceuticals
- Sector
- Healthcare
- CEO
- Aurelio Useche
- Headquarters
- 1000 Sherbrooke Street West, Montreal, QC, CA
- Industry
- Medical - Pharmaceuticals
- Sector
- Healthcare
- CEO
- Aurelio Useche
- Headquarters
- 1000 Sherbrooke Street West, Montreal, QC, CA
Relevium Technologies Inc. engages in the identification, evaluation, acquisition, and operation of brands and businesses in the health and wellness markets with a focus on e-commerce.
The company markets dietary supplements, nutraceuticals, sports nutrition products, and cosmeceuticals primarily through its Bioganix brand portfolio online; dietary supplements under the LeefyLyfe brand name; and skin care products under the Push & Pull System brand.
It also provides Relevium Senior, a geriatric brand targeting inflammatory conditions, including joints, heart, and brain; and Relevium Kids, a pediatric brand of nutraceuticals and oral nutritional supplements. The company was formerly known as BIOflex Technologies Inc. and changed its name to Relevium Technologies Inc. in December 2015.
Relevium Technologies Inc. is headquartered in Montreal, Canada.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Relevium Technologies Inc., and the rating behind it. RLLVF last traded at $0.0060; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Relevium Technologies Inc.. Starting points for Relevium Technologies Inc.: EPS -$0.03, beta 2.30 — an Medical - Pharmaceuticals name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Relevium Technologies Inc.. Relevium Technologies Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Relevium Technologies Inc.. Trailing twelve-month EPS for Relevium Technologies Inc. stands at -$0.03. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Relevium Technologies Inc.. Relevium Technologies Inc. has reported as a listed company since 2017. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Relevium Technologies Inc. valued side by side against its closest peers. Relevium Technologies Inc. is measured against Medical - Pharmaceuticals peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Relevium Technologies Inc., and how their positions are changing. At a $2.0M market value, institutional positions materially move Relevium Technologies Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Relevium Technologies Inc. executives and directors. Shares of Relevium Technologies Inc. have traded between $0.0060 and $0.22 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Relevium Technologies Inc.. Relevium Technologies Inc. is a $2.0M Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Relevium Technologies Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Relevium Technologies Inc.. Coverage tracks Relevium Technologies Inc. within Medical - Pharmaceuticals (Healthcare). Press releases and market coverage, newest first.